Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 48Neoplasm Metastasis 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Hyperglycemia 3Multiple Endocrine Neoplasia Type 1 2Advanced Breast Cancer 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1Pancreatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Exanthema 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced or Metastatic ER+ Breast Cancer 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced HER2+Breast Cancer 1

Interventions

infigratinib 1exemestane 1Rogaratinib 1Fulvestrant 1Drug Combinations 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acrocephalosyndactylia × Alpelisib × Breast × Clear all
NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Novartis

Phase 1 Completed
62 enrolled
Breast

Acrocephalosyndactylia, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡